Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs
Background: Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in sub-Saharan African kids can vary as much as 50% by age 2 years however components affecting early age of KSHV an infection should not effectively understood. Malaria throughout being pregnant has been related to hindered transplacental switch of antibodies to a number of pathogens however whether or not it impacts transplacental switch of KSHV antibodies is unknown. We aimed to find out if in utero malaria publicity decreased the switch of KSHV antibodies throughout the placenta.
Strategies: A cohort examine in Kisumu, Kenya enrolled pregnant ladies at their first antenatal clinic (ANC) go to and adopted them via supply. We included 70 KSHV-positive, HIV-negative moms and their kids. KSHV antibody ranges have been measured by ELISA (K8.1, ORF73) and multiplex assay. Transplacental switch of antibodies was measured by the wire to maternal blood ratio (CMR) of KSHV antibodies. Malaria throughout being pregnant was outlined as detection of Plasmodium falciparum (Pf) DNA at any ANC go to or supply. Amongst ladies with malaria throughout being pregnant, we examined time of final malaria an infection previous to supply and malaria incidence fee.
Outcomes: KSHV seroprevalence (constructive for K8.1 or ORF73 by ELISA) amongst pregnant ladies was 88%. Neither malaria throughout being pregnant, malaria an infection timing, nor MIR have been related to maternal supply KSHV antibody blood ranges. Maternal supply and twine blood KSHV antibody ranges have been extremely correlated however these correlations didn’t differ by malaria throughout being pregnant. KSHV transplacental antibody switch was not related to malaria throughout being pregnant, malaria an infection timing, nor MIR.
Conclusions: Malaria throughout being pregnant doesn’t seem to have an effect on switch of KSHV antibodies throughout the placenta.
Dynamic modifications in anti-SARS-CoV-2 antibodies throughout SARS-CoV-2 an infection and restoration from COVID-19
Deciphering the dynamic modifications in antibodies in opposition to SARS-CoV-2 is important for understanding the immune response in COVID-19 sufferers. Right here we analyze the laboratory findings of 1,850 sufferers to explain the dynamic modifications of the whole antibody, spike protein (S)-, receptor-binding area (RBD)-, and nucleoprotein (N)-specific immunoglobulin M (IgM) and G (IgG) ranges throughout SARS-CoV-2 an infection and restoration. The era of S-, RBD-, and N-specific IgG happens one week later in sufferers with extreme/essential COVID-19 in comparison with sufferers with gentle/average illness, whereas S- and RBD-specific IgG ranges are 1.5-fold greater in extreme/essential sufferers throughout hospitalization. The RBD-specific IgG ranges are 4-fold greater in older sufferers than in youthful sufferers throughout hospitalization.
As well as, the S- and RBD-specific IgG ranges are 2-fold greater within the recovered sufferers who’re SARS-CoV-2 RNA damaging than those that are RNA constructive. Decrease S-, RBD-, and N-specific IgG ranges are related to a decrease lymphocyte proportion, greater neutrophil proportion, and an extended period of viral shedding. Sufferers with low antibody ranges on discharge would possibly thereby have a excessive probability of being examined constructive for SARS-CoV-2 RNA after restoration. Our examine gives necessary data for COVID-19 analysis, remedy, and vaccine growth.
Throughout the coronavirus illness 2019 (COVID-19) pandemic, many international locations skilled an infection in healthcare staff (HCW) resulting from overburdened healthcare techniques. Nevertheless, whether or not contaminated HCW purchase protecting immunity in opposition to SARS-CoV-2 is unclear. Right here, we characterised SARS-CoV-2-specific antibody responses in Norwegian HCW in a potential cohort examine.
Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs
A randomized, multicentre, open-label section II proof-of-concept trial investigating the medical efficacy and security of the addition of convalescent plasma to the usual of care in sufferers hospitalized with COVID-19: the Donated Antibodies Working in opposition to nCoV (DAWn-Plasma) trial
Background: The COVID-19 pandemic has imposed an infinite burden on well being care techniques all over the world. Up to now, the administration of convalescent plasma of sufferers having recovered from SARS and extreme influenza to sufferers actively having the illness confirmed promising results on mortality and appeared secure. Whether or not or not this additionally holds true for the novel SARS-CoV-2 virus is at present unknown.
Strategies: DAWn-Plasma is a multicentre nation-wide, randomized, open-label, section II proof-of-concept medical trial, evaluating the medical efficacy and security of the addition of convalescent plasma to the usual of care in sufferers hospitalized with COVID-19 in Belgium. Sufferers hospitalized with a confirmed analysis of COVID-19 are eligible when they’re symptomatic (i.e. medical or radiological indicators) and have been recognized with COVID-19 within the 72 h earlier than examine inclusion via a PCR (nasal/nasopharyngeal swab or bronchoalveolar lavage) or a chest-CT scan displaying options suitable with COVID-19 within the absence of an alternate analysis. Sufferers are randomized in a 2:1 ratio to both customary of care and convalescent plasma (energetic remedy group) or customary of care solely. The energetic remedy group receives 2 items of 200 to 250 mL of convalescent plasma inside 12 h after randomization, with a second administration of two items 24 to 36 h after ending the primary administration. The trial goals to incorporate 483 sufferers and can recruit from 25 centres throughout Belgium. The first endpoint is the proportion of sufferers that require mechanical air flow or have died at day 15. The primary secondary endpoints are medical standing on day 15 and day 30 after randomization, as outlined by the WHO Development 10-point ordinal scale, and security of the administration of convalescent plasma.
Description: Major intrinsic protein is a member of the water-transporting aquaporins as well as the original member of the MIP family of channel proteins. The function of the fiber cell membrane protein encoded by this gene is undetermined, yet this protein is speculated to play a role in intracellular communication. The MIP protein is expressed in the ocular lens and is required for correct lens function. This gene has been mapped among aquaporins AQP2, AQP5, and AQP6, in a potential gene cluster at 12q13.
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: Matrix metalloproteinases (MMPs) are a family of endoproteases that require zinc and calcium for expressing catalytic activity. These enzymes play a central role in the maintenance and remodeling of the extracellular matrix. Elevated expression of their activity, caused either by up-regulation of their expression or down-regulation of their cognate inhibitors, has been implicated in various degenerative disorders, including arthritis, cardiovascular disease, skeletal growth-plate disorders, and cancer metastasis. MMP-3 degrades fibronectin, laminin, collagens III, IV, and X, and cartilage proteoglycans. Recombinant human MMP-3 is a 42.8 kDa protein containing the entire catalytic N-terminal domain and the C-terminal domain (378 amino acids).
Description: Interleukin-3 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 154 amino acids fragment (20-152) and having a total molecular mass of 17.3kDa and fused with a 20 aa N-terminal His tag. ;The IL3 His is purified by proprietary chromatographic techniques.
Description: MIP-3 alpha is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and signals through the CCR6 receptor. MIP-3 alpha is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant murine MIP-3 alpha is a 7.9 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3 alpha is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and signals through the CCR6 receptor. MIP-3 alpha is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant murine MIP-3 alpha is a 7.9 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3 beta is a CC chemokine that is expressed in the thymus, lymph nodes and in activated bone marrow stromal cells and signals through the CCR7 receptor. MIP-3 beta is a chemoattractant for T and B lymphocytes and myeloid progenitor cells. Human MIP-3 beta is active on murine cells. Recombinant murine MIP-3 beta is a 9.2 kDa protein containing 83 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3 beta is a CC chemokine that is expressed in the thymus, lymph nodes and in activated bone marrow stromal cells and signals through the CCR7 receptor. MIP-3 beta is a chemoattractant for T and B lymphocytes and myeloid progenitor cells. Human MIP-3 beta is active on murine cells. Recombinant murine MIP-3 beta is a 9.2 kDa protein containing 83 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3 alpha is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3 alpha is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 alpha is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3 alpha is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3 alpha is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 alpha is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3 beta is a CC chemokine that is expressed in the thymus, lymph nodes and in activated bone marrow stromal cells and signals through the CCR7 receptor. MIP-3 beta is a chemoattractant for T and B lymphocytes and myeloid progenitor cells. Human MIP-3 beta is active on murine cells. Recombinant human MIP-3 beta is an 8.8 kDa protein containing 77 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3 beta is a CC chemokine that is expressed in the thymus, lymph nodes and in activated bone marrow stromal cells and signals through the CCR7 receptor. MIP-3 beta is a chemoattractant for T and B lymphocytes and myeloid progenitor cells. Human MIP-3 beta is active on murine cells. Recombinant human MIP-3 beta is an 8.8 kDa protein containing 77 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3α is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3α is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3α is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3β is a CC chemokine that is expressed in the thymus, lymph nodes and in activated bone marrow stromal cells and signals through the CCR7 receptor. MIP-3β is a chemoattractant for T and B lymphocytes and myeloid progenitor cells. Human MIP-3β is active on murine cells. Recombinant human MIP-3β is an 8.8 kDa protein containing 77 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.
Description: Recombinant MIP-3 alpha (CCL20) is a disulfide-linked monomeric protein consisting of 71 amino acid residues and migrates as an approximately 8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 alpha mature chain was expressed in E. coli.
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.
Description: A polyclonal antibody against MIP. Recognizes MIP from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/5000
Description: A polyclonal antibody against MIP. Recognizes MIP from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:20-1:100
Description: A polyclonal antibody against MIP. Recognizes MIP from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:500-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody against MIP. Recognizes MIP from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody against mip. Recognizes mip from Legionella pneumophila. This antibody is Unconjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against MIP. Recognizes MIP from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody against MIP. Recognizes MIP from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB
Description: A polyclonal antibody against MIP. Recognizes MIP from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:200-1:500, IF:1:50-1:200
Description: ELISA based test for quantitative detection of FSH (Human Follicle-stimulating hormone)
×
Dialogue: This trial will both present assist or discourage the usage of convalescent plasma as an early intervention for the remedy of hospitalized sufferers with COVID-19 an infection.
